Press releases
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
- Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments
- Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
Key statistics
On Friday, Sarepta Therapeutics Inc (AB3A:FRA) closed at 107.45, -18.66% below its 52-week high of 132.10, set on May 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 107.45 |
---|---|
High | 107.45 |
Low | 107.45 |
Bid | 114.00 |
Offer | 114.35 |
Previous close | 109.50 |
Average volume | 279.60 |
---|---|
Shares outstanding | 94.52m |
Free float | 89.83m |
P/E (TTM) | 1,502.70 |
Market cap | 11.32bn USD |
EPS (TTM) | 0.0797 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 07:02 BST.
More ▼